Shanghai Fosun Pharmaceutical Industrial Development
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (30)
FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration
Started: 6/30/2025
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Started: 6/20/2023
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
Started: 12/31/2021
A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.
Started: 12/10/2026
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Started: 6/15/2026
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
Started: 1/29/2026
To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
Started: 9/28/2023
FXS6837 for the Treatment of IgAN Patients
Started: 3/31/2026
A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
Started: 5/30/2025
FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms
Started: 8/16/2023
A Phase IIa Study in Primary IgA Nephropathy Patients
Started: 12/31/2024
FXS6837 for the Treatment for IgAN Patients（Longterm Study）
Started: 9/30/2026
Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo
Started: 10/30/2026
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
Started: 1/14/2025
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
Started: 8/15/2024
Phase I Study of FXS0683 in the Treatment of Blood Tumors
Started: 6/2/2026
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
Started: 5/15/2026
Phase I Study of FXS887 in the Treatment of Solid Tumors
Started: 1/5/2026
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
Started: 10/11/2019
XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation
Started: 5/23/2025
The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations
Started: 7/15/2025
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Started: 6/12/2025
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Started: 3/26/2021
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Started: 3/21/2019
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
Started: 7/23/2018
Mass Balance Study of [¹⁴C]FXS4640 in Healthy Adult Males
Started: 10/25/2026